US 12,221,493 B2
Immunotherapy against several tumors including neuronal and brain tumors
Toni Weinschenk, Aichwald (DE); Oliver Schoor, Tuebingen (DE); Claudia Trautwein, Wuelfrath (DE); Norbert Hilf, Kirchentellinsfurt (DE); Steffen Walter, Houston, TX (US); and Harpreet Singh, Munich (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed on Apr. 23, 2021, as Appl. No. 17/238,806.
Application 14/562,156 is a division of application No. 13/346,598, filed on Jan. 9, 2012, granted, now 8,961,985, issued on Feb. 24, 2015.
Application 13/346,598 is a division of application No. 12/571,776, filed on Oct. 1, 2009, granted, now 8,119,139, issued on Feb. 21, 2012.
Application 17/238,806 is a continuation of application No. 16/136,008, filed on Sep. 19, 2018, abandoned.
Application 16/136,008 is a continuation of application No. 14/562,156, filed on Dec. 5, 2014, granted, now 10,227,381, issued on Mar. 12, 2019.
Claims priority of provisional application 61/105,928, filed on Oct. 16, 2008.
Claims priority of application No. 08017305 (EP), filed on Oct. 1, 2008; application No. 08017921 (EP), filed on Oct. 13, 2008; and application No. PCT/EP2009/006980 (WO), filed on Sep. 28, 2009.
Prior Publication US 2021/0238227 A1, Aug. 5, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61M 5/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/74 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01); G01N 33/574 (2006.01); C07K 7/00 (2006.01)
CPC C07K 7/06 (2013.01) [A61K 35/17 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); A61M 5/002 (2013.01); C07K 7/08 (2013.01); C07K 14/70539 (2013.01); C12N 5/0638 (2013.01); C12N 5/0639 (2013.01); G01N 33/57492 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55588 (2013.01); A61K 2039/572 (2013.01); A61K 2039/605 (2013.01); A61K 2039/6081 (2013.01); A61K 2039/6093 (2013.01); C07K 7/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/40 (2013.01); C12N 2501/50 (2013.01); Y02A 50/30 (2018.01)] 17 Claims
 
1. An isolated peptide consisting of the amino acid sequence ALWAWPSEL (SEQ ID NO: 5) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.